16/03/2026
Important Update from Helius Therapeutics
We are disappointed to announce that as of 11 March 2026, Helius Therapeutics Limited has entered voluntary administration, marking a difficult moment for the team and the wider medicinal cannabis industry.
The decision follows sustained commercial pressures within the challenging regulatory and commercial environment for medicinal cannabis. As part of the process Helius Therapeutics will close its East Tamaki manufacturing facility.
From the beginning, our mission has been to improve access to evidence-based medicinal cannabis treatments for New Zealand patients. We are proud of the role we have played in and hope the industry will continue evolve and benefit Kiwi patients across New Zealand.
We are deeply grateful to the healthcare professionals, partners, and most importantly our patients who have supported us throughout the journey.
At this stage, operations will continue in a limited capacity.
Patients should check with their dispensing pharmacy regarding stock availability. If you have any questions, please contact [email protected]
The voluntary administration does not impact the clinic business operating under Cannaplus, which continues to operate independently and provide prescribing and patient care services across New Zealand.